(NASDAQ:CERT), RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research. With more than 200 papers authored by Certara scientists* this past year and 11 Certara scientists included on the 2025 update of Stanford/Elsevier's ranking of the top […]
(NASDAQ:OPRT), 5.77% average yield, demonstrates Oportun's continued access to low-cost funding Third consecutive transaction with AAA rating on most senior bonds SAN CARLOS, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) — Oportun (Nasdaq: OPRT), a mission-driven financial services company, today announced the issuance of $441 million of two-year revolving fixed rate asset-backed notes secured by a
(TSX-V:ROMJ),(OTC US:ROMJF),(Other OTC:ROMJF), 40% increase in cultivation capacity expected to drive revenue and EBITDA growth in Rubicon's premium cannabis products The Company also announces the naming of cultivation facilities to Pacifica (previously “Delta Facility”) and Cascadia (previously “Hope Facility”). VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF)
(NasdaqGM:BCAB), Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS) Prolonged tumor control with increasing doses of BA3182; confirmed partial response (cPR) at 0.6 mg in a patient with intrahepatic cholangiocarcinoma without progression for >6 months​ Maximally tolerated dose not yet defined; dose escalation continues; currently testing 1.8
Preclinical results support 6-month dosing, demonstrating VLTR-559's substantially longer ocular half-life, with high drug concentrations retained in the retina compared to current anti-VEGF standard of care VLTR-559 potency was maintained three-fold longer than aflibercept in preclinical models VLTR-559 was well tolerated at target clinical dose with a safety profile similar to approved short-acting anti-VEGF therapies
(NASDAQ:SBET), FalconX and Bridgewater Alum Matthew Sheffield Named Chief Investment Officer Former Bain Capital Crypto Head of Marketing Mandy Campbell Named Chief Marketing Officer Consensys and J.P. Morgan Veteran Michael Camarda Named Chief Development Officer Minneapolis, MN, Oct. 20, 2025 (GLOBE NEWSWIRE) — SharpLink Gaming, Inc. (Nasdaq: SBET) (“SharpLink” or the “Company”), one of the
(NASDAQ:AMRK), EL SEGUNDO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) — A-Mark Precious Metals, Inc. (NASDAQ: AMRK) (A-Mark), a leading fully integrated precious metals platform, will hold a conference call on Thursday, November 6, 2025, at 4:30 p.m. Eastern time to discuss results for the fiscal first quarter ended September 30, 2025. Financial results will be
(NASDAQ:SUNS), WEST PALM BEACH, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) — Sunrise Realty Trust, Inc. (“SUNS” or the “Company”) (Nasdaq: SUNS), a lender on the Tannenbaum Capital Group (“TCG”) Real Estate platform, today announced that it has committed $25.6 million to a $36.6 million senior loan commitment originated by TCG Real Estate for the financing
Denver, CO, Oct. 20, 2025 (GLOBE NEWSWIRE) — The University of Colorado Denver (CU Denver) Business School, today announced the renowned faculty shaping curriculum for its newly launched Executive MBA in Aviation, bringing together a team of industry veterans and academic leaders to guide the program's inaugural class. The faculty includes former and current airline
(NASDAQ:CRVO), BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present at the Emerging Growth Conference, being held virtually on Wednesday, October 22, 2025. Presentation